Experts highlight unmet needs and emerging role of antibody drug conjugates in endometrial cancer

Experts note that significant unmet needs persist in endometrial cancer even as antibody drug conjugates (ADCs) begin to expand treatment options.

They suggest ADCs could address gaps in recurrent disease, but warn that unusual toxicities demand rapid clinician education and early intervention to keep patients on therapy safely.

A key unanswered question is whether an ADC retains activity after a patient has been exposed to another ADC with a similar payload, especially as more targets become clinically relevant. The discussion also underscores the difficulty of choosing among multiple biomarkers when a tumor expresses several actionable targets.

Faculty consider whether these therapies might eventually move earlier in the treatment pathway, potentially reducing reliance on more toxic multidrug regimens.